DES MOINES — Kemin applauds the findings of a new human study presented by Biofortis, a global contract research organization, suggesting that the use of a patent-pending spearmint extract containing phenolic complex K110-42 may help improve cognitive health and cognitive performance in older adults. These study results were presented in a poster session, sponsored by the American Society for Nutrition, at Experimental Biology April 26-30 in San Diego.
The study, “Tolerance and Cognitive Function Effects of a Proprietary Spearmint Extract in Men and Women with Self-Reported Memory Impairment – A Pilot Study,” assessed both the tolerability of Kemin Industries’ proprietary ingredient as well as its effects on cognition. Tolerance was assessed by evaluation of gastrointestinal (GI) tolerability, adverse events, and clinical laboratory tests at baseline and end of treatment. Acute and chronic cognitive effects were evaluated using validated computerized testing models at multiple time points.
After 30 days of supplementation, Biofortis researchers found that subjects saw improvements in subjective memory scores and in computer cognitive tests designed to measure reasoning, attention, and planning. In addition to these results, researchers also saw acute benefits on the first day of supplementation where there was statistically significant improvement in attention, concentration and planning scores at two and four hours post-dose, compared to pre-dose. Subjects did not experience any GI issues or adverse events related to the product.
